EA201200689A1 - Способ уменьшения желудочно-кишечного воспаления с помощью бактерий bifidobacterium animalis или кисло-молочного продукта, содержащего такие бактерии - Google Patents

Способ уменьшения желудочно-кишечного воспаления с помощью бактерий bifidobacterium animalis или кисло-молочного продукта, содержащего такие бактерии

Info

Publication number
EA201200689A1
EA201200689A1 EA201200689A EA201200689A EA201200689A1 EA 201200689 A1 EA201200689 A1 EA 201200689A1 EA 201200689 A EA201200689 A EA 201200689A EA 201200689 A EA201200689 A EA 201200689A EA 201200689 A1 EA201200689 A1 EA 201200689A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bacteria
gastrointestinal inflammation
product containing
milk product
help
Prior art date
Application number
EA201200689A
Other languages
English (en)
Other versions
EA021890B1 (ru
Inventor
Патрик Веига
Изабель Шамбо
Артём Хлебников
Лори Х. Глимчер
Венди С. Гарретт
Original Assignee
Компани Жервэ Данон
Президент Энд Фэллоуз Оф Харвард Коллидж
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Компани Жервэ Данон, Президент Энд Фэллоуз Оф Харвард Коллидж filed Critical Компани Жервэ Данон
Publication of EA201200689A1 publication Critical patent/EA201200689A1/ru
Publication of EA021890B1 publication Critical patent/EA021890B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к способу профилактики, лечения и уменьшения желудочно-кишечного воспаления у субъекта путем введения специальных Bifidobacterium бактерий, в том числе кисло-молочного продукта, содержащего упомянутые специальные Bifidobacterium бактерии для профилактики, лечения и уменьшения желудочно-кишечного воспаления, в частности для профилактики и лечения болезни воспаленного кишечника (IBD), язвенного колита (UC) и болезни Крона (CD) и для профилактики и лечения синдрома раздраженной кишки (IBS).
EA201200689A 2009-11-02 2009-11-02 Способ предотвращения и/или лечения болезни воспаленного кишечника, язвенного колита и болезни крона EA021890B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2009/056007 WO2011051760A1 (en) 2009-11-02 2009-11-02 Method for reducing gastro-intestinal inflammation using bifidobacterium animalis bacteria or a fermented dairy product comprising such bacteria

Publications (2)

Publication Number Publication Date
EA201200689A1 true EA201200689A1 (ru) 2012-09-28
EA021890B1 EA021890B1 (ru) 2015-09-30

Family

ID=42102362

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200689A EA021890B1 (ru) 2009-11-02 2009-11-02 Способ предотвращения и/или лечения болезни воспаленного кишечника, язвенного колита и болезни крона

Country Status (8)

Country Link
US (1) US8685388B2 (ru)
EP (1) EP2496241B1 (ru)
CN (1) CN102711778B (ru)
BR (1) BR112012010398A2 (ru)
EA (1) EA021890B1 (ru)
ES (1) ES2436620T3 (ru)
PL (1) PL2496241T3 (ru)
WO (1) WO2011051760A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011148219A1 (en) * 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving the enteric nervous system
US9814756B2 (en) 2012-06-15 2017-11-14 Temple University—Of the Commonwealth System of Higher Education Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium
WO2014096901A1 (en) * 2012-12-18 2014-06-26 Compagnie Gervais Danone Strain of bifidobacterium animalis ssp. animalis
WO2014094279A1 (en) * 2012-12-20 2014-06-26 Companie Gervais Danone Use of bifidobacterium animalis for treating or preventing body weight gain and insulin resistance
WO2016170394A1 (en) * 2015-04-23 2016-10-27 Compagnie Gervais Danone Composition for reducing intestinal gas production
EP3341000A4 (en) * 2015-08-24 2019-02-20 Nubyiota LLC SYSTEMS AND METHODS FOR THE TREATMENT OF DYSBIOSIS USING BACTERIAL POPULATIONS DERIVED FROM FECES
CN107574133A (zh) * 2017-05-05 2018-01-12 南昌大学 动物双歧杆菌m2017064及其在缓解慢性肾脏疾病药物的应用
JP7285096B2 (ja) * 2018-03-28 2023-06-01 森永乳業株式会社 ストレス緩和用組成物並びに該ストレス緩和用組成物を用いた医薬品組成物及び飲食品組成物
WO2020102472A1 (en) * 2018-11-15 2020-05-22 President And Fellows Of Harvard College Methods and compositions related to targeting ffar2 and ilc3 populations for the treatment of a gastrointestinal disease
TWI754302B (zh) * 2019-06-21 2022-02-01 大江生醫股份有限公司 乳雙歧桿菌tci604及其代謝產物的應用
IT201900016811A1 (it) * 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
CN113430133B (zh) * 2021-06-24 2023-06-23 微康益生菌(苏州)股份有限公司 一种能够缓解溃疡性结肠炎的复合益生菌、制备方法及其应用
CN113368139A (zh) * 2021-07-02 2021-09-10 微康益生菌(苏州)股份有限公司 一种具有缓解肠易激综合征功效的微生物复合物及其制备方法和应用
CN113736697B (zh) * 2021-09-01 2022-05-24 哈尔滨葵花药业有限公司 一株预防或治疗结肠炎的乳双歧杆菌及其应用
CN115363094A (zh) * 2021-11-30 2022-11-22 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在预防和/或改善胃炎中的应用
CN117264853B (zh) * 2023-11-17 2024-02-27 中国农业大学 一种缓解溃疡性结肠炎的富硒动物双歧杆菌h15的筛选方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2811333B1 (fr) 2000-07-04 2003-01-10 Gervais Danone Sa Microorganismes ayant une action modulatrice de la glycosylation de surface des cellules intestinales et methode de selection desdits microorganismes
MX2007006086A (es) * 2004-11-25 2007-07-11 Unilever Nv Anticuerpos de cadena pesada y de dominio.
US20090035288A1 (en) * 2005-07-20 2009-02-05 Ruud Albers Edible product containing beneficial bacteria
US20090110663A1 (en) * 2007-10-24 2009-04-30 Halow George M Method for treatment of bowel disorders
ES2395838T3 (es) * 2007-12-21 2013-02-15 Compagnie Gervais Danone Método para disminuir el contorno abdominal administrando una bacteria del tipo Bifidobacterium
US20090238796A1 (en) * 2008-03-24 2009-09-24 Tamara Vasilevna Maculevich Preparation for treatment of non-infectious inflammatory intestinal diseases

Also Published As

Publication number Publication date
CN102711778A (zh) 2012-10-03
WO2011051760A1 (en) 2011-05-05
PL2496241T3 (pl) 2014-03-31
US8685388B2 (en) 2014-04-01
CN102711778B (zh) 2015-06-24
ES2436620T3 (es) 2014-01-03
EP2496241A1 (en) 2012-09-12
US20120308523A1 (en) 2012-12-06
BR112012010398A2 (pt) 2016-07-12
EA021890B1 (ru) 2015-09-30
EP2496241B1 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
EA201200689A1 (ru) Способ уменьшения желудочно-кишечного воспаления с помощью бактерий bifidobacterium animalis или кисло-молочного продукта, содержащего такие бактерии
IN2012DN04950A (ru)
CA2848762C (en) Method for treatment of disorders of the gastrointestinal system
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
EA201291441A1 (ru) Пробиотические штаммы для применения при улучшении состояния кишечной нервной системы
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MX2016002765A (es) Empleo de una composicion que comprende microorganismos para aumentar la produccion intestinal de acido butirico, acido folico o niacina y/o disminuir la produccion intestinal de acido succinico.
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
BR112014008819A2 (pt) métodos para o tratamento de síndrome de vazamento vascular e câncer
WO2012047631A3 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
UA109876C2 (ru) Композиция, содержащая bifidobacterium longum cncm i-2 618, для профилактики и лечения иммунных расстройств
IT1398553B1 (it) Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
MX2010003013A (es) Inhibicion de angiogenesis.
NZ708928A (en) Mannose derivatives for treating bacterial infections
TN2011000482A1 (en) Organic compounds and their uses
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
EA201992175A1 (ru) Композиции и способы, включающие пробиотические молекулы
MX2011005527A (es) Uso de la bacteria de acido lactico para tratar o prevenir el eczema.
MY151104A (en) Novel use
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
PH12014502680A1 (en) Polysaccharide compositions and methods of use
IN2014DN08385A (ru)
MA40592A (fr) Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY